Kazia Therapeutics (KZIA) grants CFO 200,000 options vesting to 2029

Rhea-AI Filing Summary

Kazia Therapeutics reported that Chief Financial Officer James E. Levine received an award of 200,000 employee stock options over ADSs, with an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026, and the remaining two-thirds vest in equal yearly tranches on each anniversary of that date.

The options were granted for no consideration and expire on June 19, 2029. All options held by Levine will be forfeited if he voluntarily leaves the company before the first anniversary of the commencement date. Following this grant, he holds 200,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Levine James E.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	200,000	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 200,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 200,000 options Exercise price: $13.86 per ADS Total derivative holdings after grant: 200,000 options +2 more

5 metrics

Options granted 200,000 options Employee stock option award over ADSs to CFO

Exercise price $13.86 per ADS Strike price for newly granted options

Total derivative holdings after grant 200,000 options Total options reported following transaction

Initial vesting date June 1, 2026 One-third of options vest on commencement date

Expiration date June 19, 2029 Expiry of granted options over ADSs

Key Terms

Employee Stock Option (right to buy), ADSs, vest, Commencement Date

4 terms

Employee Stock Option (right to buy) financial

"security_title: "Employee Stock Option (right to buy)""

ADSs financial

"Represents an award of 200,000 options over ADSs on June 19, 2026"

vest financial

"One-third of the options vest on June 1, 2026"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Commencement Date financial

"June 1, 2026 (the "Commencement Date") and the remaining two-thirds vest"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 06:48 PM Accepted by SEC EDGAR 06/23/2026 - 06:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levine James E.

(Last) (First) (Middle)

THREE INTERNATIONAL TOWERS, LEVEL 24

300 BARANGAROO AVENUE

(Street)

SYDNEY NSW 2000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
KAZIA THERAPEUTICS LTD [ KZIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol
[KZIA]

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$13.86	06/19/2026		A		200,000(1)		(1)	(1)	ADSs	200,000	$0	200,000	D

Explanation of Responses:

1. Represents an award of 200,000 options over ADSs on June 19, 2026, at an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029.

	/s/ James Levine	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Kazia Therapeutics (KZIA) disclose in this Form 4 for James E. Levine?

Kazia Therapeutics disclosed that CFO James E. Levine received 200,000 employee stock options over ADSs at an exercise price of $13.86 per ADS. These options were granted for no consideration and represent a compensation-related equity award.

How many stock options did Kazia CFO James E. Levine receive?

James E. Levine received an award of 200,000 employee stock options over ADSs. All 200,000 options are directly held and, after this grant, his total reported derivative holdings shown in this filing are 200,000 options linked to ADSs.

What is the exercise price of the new Kazia (KZIA) stock options granted to the CFO?

The options granted to the Kazia CFO have an exercise price of $13.86 per ADS. This means Levine can buy ADSs at $13.86 each once the options vest, provided he remains employed under the award’s conditions.

When do James E. Levine’s Kazia stock options vest?

One-third of the options vest on June 1, 2026, called the commencement date. The remaining two-thirds vest in equal yearly tranches on each anniversary of that date, creating a multi-year vesting schedule tied to continued service.

When do the Kazia Therapeutics CFO’s options over ADSs expire?

The options awarded to the CFO expire on June 19, 2029. If they are not exercised by that date, they lapse and become worthless, so this expiration sets the outer time limit for potential exercise of the award.

What happens to James E. Levine’s Kazia options if he leaves early?

All options held by James E. Levine will be forfeited if he voluntarily leaves Kazia Therapeutics before the first anniversary of the commencement date, June 1, 2027. This condition encourages at least one year of continued service after vesting begins.